Development · 6 Nov 2026
ZYDUSLIFE, full dossier6 publishers have reported this development. Each act of reporting is below, cited.
Zydus Lifesciences posted a 26.6 per cent decline in consolidated net profit to ₹925.5 crore in the September quarter.
Net profit of Zydus Lifesciences declined 26.47% to Rs 925.50 crore in the quarter ended September 2026 as against Rs 1258.60 crore during the previous quarter ended September 2025.
Zydus Lifesciences reported a 29% year-on-year increase in revenue from operations to Rs 7,909 crore for the September quarter, but net profit declined 27% to Rs 925 crore due to a rise in expenses.
Zydus Lifesciences reported a 27% drop in Q2 profit.
Zydus Lifesciences reported a 29.2% year-on-year increase in revenue to ₹7,910 crore in Q2 FY27, compared with ₹6,123 crore in the corresponding quarter last year.
Zydus Lifesciences' consolidated net profit declined 26.6 per cent year-on-year to Rs 925.5 crore in the July-September quarter.
16 Nov 2026 · 2 publishers
Bank of India is quoting at Rs 154.3, up 1.91% on the day as on 12:39 IST on the NSE.
14 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.